Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stephen Green

Showing results (41-50 of 60) with videos related to

Pageof 6
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 26, 2015
First-in-Human Pharmacokinetic and Pharmacodynamic Study of the Dual m-TORC 1/2 Inhibitor AZD2014Bristi Basu, Emma Dean, Martina Puglisi, et al.
Bioorganic & Medicinal Chemistry Letters|July 5, 2014
Discovery of 9-(1-anilinoethyl)-2-morpholino-4-oxo-pyrido[1,2-a]pyrimidine-7-carboxamides as PI3Kβ/δ inhibitors for the treatment of PTEN-deficient tumoursBernard Barlaam, Sabina Cosulich, Sébastien Degorce, et al.
Structure (London, England : 1993)|December 6, 2003
Insights into cyclin groove recognition: complex crystal structures and inhibitor design through ligand exchangeGeorge Kontopidis, Martin J I Andrews, Campbell McInnes, et al.
Bioorganic & Medicinal Chemistry Letters|March 22, 2016
Discovery of a series of 8-(2,3-dihydro-1,4-benzoxazin-4-ylmethyl)-2-morpholino-4-oxo-chromene-6-carboxamides as PI3Kβ/δ inhibitors for the treatment of PTEN-deficient tumoursBernard Barlaam, Sabina Cosulich, Sébastien Degorce, et al.
Oncotarget|October 21, 2017
Pre-clinical pharmacology of AZD3965, a selective inhibitor of MCT1: DLBCL, NHL and Burkitt's lymphoma anti-tumor activityNicola J Curtis, Lorraine Mooney, Lorna Hopcroft, et al.
Bioorganic & Medicinal Chemistry Letters|February 26, 2008
Synthesis and SAR of 1-acetanilide-4-aminopyrazole-substituted quinazolines: selective inhibitors of Aurora B kinase with potent anti-tumor activityKevin M Foote, Andrew A Mortlock, Nicola M Heron, et al.
Bioorganic & Medicinal Chemistry Letters|May 21, 2017
Discovery of a novel aminopyrazine series as selective PI3Kα inhibitorsBernard Barlaam, Sabina Cosulich, Martina Fitzek, et al.
Bioorganic & Medicinal Chemistry Letters|August 28, 2003
Imidazo[1,2-a]pyridines: a potent and selective class of cyclin-dependent kinase inhibitors identified through structure-based hybridisationMalcolm Anderson, John F Beattie, Gloria A Breault, et al.
Molecular Cancer Therapeutics|February 4, 2016
Intermittent High-Dose Scheduling of AZD8835, a Novel Selective Inhibitor of PI3Kα and PI3Kδ, Demonstrates Treatment Strategies for PIK3CA-Dependent Breast CancersKevin Hudson, Urs J Hancox, Cath Trigwell, et al.
Journal of Medicinal Chemistry|December 17, 2014
Discovery of (R)-8-(1-(3,5-difluorophenylamino)ethyl)-N,N-dimethyl-2-morpholino-4-oxo-4H-chromene-6-carboxamide (AZD8186): a potent and selective inhibitor of PI3Kβ and PI3Kδ for the treatment of PTEN-deficient cancersBernard Barlaam, Sabina Cosulich, Sébastien Degorce, et al.
Pageof 6

Showing results (41-50 of 60) with videos related to

Sort By:
Pageof 6
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 26, 2015
First-in-Human Pharmacokinetic and Pharmacodynamic Study of the Dual m-TORC 1/2 Inhibitor AZD2014Bristi Basu, Emma Dean, Martina Puglisi, et al.
Bioorganic & Medicinal Chemistry Letters|July 5, 2014
Discovery of 9-(1-anilinoethyl)-2-morpholino-4-oxo-pyrido[1,2-a]pyrimidine-7-carboxamides as PI3Kβ/δ inhibitors for the treatment of PTEN-deficient tumoursBernard Barlaam, Sabina Cosulich, Sébastien Degorce, et al.
Structure (London, England : 1993)|December 6, 2003
Insights into cyclin groove recognition: complex crystal structures and inhibitor design through ligand exchangeGeorge Kontopidis, Martin J I Andrews, Campbell McInnes, et al.
Bioorganic & Medicinal Chemistry Letters|March 22, 2016
Discovery of a series of 8-(2,3-dihydro-1,4-benzoxazin-4-ylmethyl)-2-morpholino-4-oxo-chromene-6-carboxamides as PI3Kβ/δ inhibitors for the treatment of PTEN-deficient tumoursBernard Barlaam, Sabina Cosulich, Sébastien Degorce, et al.
Oncotarget|October 21, 2017
Pre-clinical pharmacology of AZD3965, a selective inhibitor of MCT1: DLBCL, NHL and Burkitt's lymphoma anti-tumor activityNicola J Curtis, Lorraine Mooney, Lorna Hopcroft, et al.
Bioorganic & Medicinal Chemistry Letters|February 26, 2008
Synthesis and SAR of 1-acetanilide-4-aminopyrazole-substituted quinazolines: selective inhibitors of Aurora B kinase with potent anti-tumor activityKevin M Foote, Andrew A Mortlock, Nicola M Heron, et al.
Bioorganic & Medicinal Chemistry Letters|May 21, 2017
Discovery of a novel aminopyrazine series as selective PI3Kα inhibitorsBernard Barlaam, Sabina Cosulich, Martina Fitzek, et al.
Bioorganic & Medicinal Chemistry Letters|August 28, 2003
Imidazo[1,2-a]pyridines: a potent and selective class of cyclin-dependent kinase inhibitors identified through structure-based hybridisationMalcolm Anderson, John F Beattie, Gloria A Breault, et al.
Molecular Cancer Therapeutics|February 4, 2016
Intermittent High-Dose Scheduling of AZD8835, a Novel Selective Inhibitor of PI3Kα and PI3Kδ, Demonstrates Treatment Strategies for PIK3CA-Dependent Breast CancersKevin Hudson, Urs J Hancox, Cath Trigwell, et al.
Journal of Medicinal Chemistry|December 17, 2014
Discovery of (R)-8-(1-(3,5-difluorophenylamino)ethyl)-N,N-dimethyl-2-morpholino-4-oxo-4H-chromene-6-carboxamide (AZD8186): a potent and selective inhibitor of PI3Kβ and PI3Kδ for the treatment of PTEN-deficient cancersBernard Barlaam, Sabina Cosulich, Sébastien Degorce, et al.
Pageof 6